Key terms
About AUTL
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AUTL news
Yesterday
1:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)
Yesterday
8:42am ET
Autolus Therapeutics Shares Q1 Results and Corporate Update
Yesterday
7:05am ET
Options Volatility and Implied Earnings Moves Today, May 17, 2024
Yesterday
7:02am ET
Autolus Therapeutics reports Q1 EPS (24c), consensus (5c)
May 13
9:38am ET
Autolus files to delay quarterly report, cancels earnings call
May 13
7:32am ET
Autolus Therapeutics Announces Q1 2024 Financial Update
May 13
7:19am ET
Autolus Therapeutics announces delay to Q1 earnings release, conference call
Apr 12
6:06am ET
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Apr 02
7:16am ET
Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel
Apr 01
7:22am ET
Autolus Therapeutics Announces Board Leadership Changes
Apr 01
7:19am ET
Autolus chairman John Johnson steps down, Mike Bonney succeeds
Mar 28
4:22pm ET
Autolus files to sell 33.33M American Depositary Shares for holders
Mar 25
8:41am ET
Aveo Oncology appoints Edgar Braendle as CMO
Mar 18
9:22am ET
Autolus Therapeutics price target raised to $10 from $9 at Truist
Mar 14
1:40pm ET
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
Mar 14
12:42pm ET
Autolus Therapeutics Announces Annual Results and CDO Resignation
Mar 12
7:28am ET
Autolus Therapeutics receives MHRA certification for Nucleus site
Mar 11
7:08am ET
Autolus Therapeutics announces publication in Blood Cancer Journal
Feb 22
7:21am ET
Autolus Therapeutics announces publication in Nature Communications
No recent press releases are available for AUTL
AUTL Financials
Key terms
Ad Feedback
AUTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AUTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range